In a preclinical model of head and neck cancer, long-term metformin treatment reduces tumor growth velocity, increases tumor infiltrating lymphocyte levels, and increases the CD8+/T-reg ratio (a measure of immune cell upregulation) thereby creating local and systemic immune effects (132). Here, CD8A is linked to neoplasm.